Solid state interactions between the proton pump inhibitor omeprazole and various enteric coating polymers

Journal of Pharmaceutical Sciences

Volumn 95, Issue 6, 2006, Pages 1342-1353

  Stroyer, A ^a   McGinity, J W ^b   Leopold, C S ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Drug polymer blends; DSC; Enteric coating polymers; FTIR; HPLC; Microenvironmental pH; Omeprazole degradation; Physical characterization; Solid state interactions; Stability

Indexed keywords

CITRATE SODIUM; EUDRAGIT; EUDRAGIT RS; HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE; OMEPRAZOLE; POLYMER; PROTON PUMP INHIBITOR; SHELLAC;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG STABILITY; ENTERIC COATED TABLET; ENVIRONMENTAL TEMPERATURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; PARTICLE SIZE; PH; SENSITIVITY ANALYSIS; SOLID STATE; SPECTRAL SENSITIVITY;

EID: 33745028850     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20450     Document Type: Article

References (40)

1. Brändström A, Lindberg P, Junggren UC. 1985. Structure activity relationships of substituted benzimidazoles. Scand J Gastroenterol 20:15-22.
2. European Pharmacopoeia. 2005.
3. Pilbrant A. 1985. Development of an oral formulation of omeprazole. Scand J Gastroenterol 20:113-119.
4. Mathew M, Das Gupta V, Bailey RE. 1995. Stability of omeprazole solutions at various pH values as determined by High-Performance Liquid Chromatography. Drug Dev Ind Pharm 21:965-971.
5. Lövgren KI, Pilbrant AG, Yasumura M, Morigaki S, Oda M, Ohishi N. 1987. New pharmaceutical preparation for oral use. EP-Patent 0 2479 83 B1.
6. Davidson AG, McCallum A. 1996. A survey of the stability of omeprazole products from 13 countries. Drug Dev Ind Pharm 22:1173-1185.
7. Ekpe A, Jacobsen T. 1999. Effect of various salts on the stability of lansoprazole, omeprazole, and pantoprazole as determined by high-performance liquid chromatography. Drug Dev Ind Pharm 25:1057-1065.
8. Hamdan II. 2001. In vitro study of the interaction between omeprazole and the metal ions Zn(II), Cu(II), and Co(II). Pharmazie 56:877-881.
9. Storpirtis S, Rodrigues D. 1998. In vitro evaluation of dissolution properties and degradation products of omeprazole in enteric-coated pellets. Drug Dev Ind Pharm 24:1101-1107.
10. Gordon MS, Fratis A, Goldblum R, Jung D, Schwartz KE, Chowhan ZT. 1995. In vivo and in vitro evaluation of four different aqueous polymeric dispersions for producing an enteric coated tablet. Int J Pharm 115:29-34.
11. Erickson M, Josefson L. 1998. Pharmaceutical formulation of omeprazole. US-Patent 6,090,827.
12. Lee F-Y, Chen S-C, Kuo H-C. 2000. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same. US-Patent 6,228,400 B1.
13. Govender T, Dangor CM, Chetty DJ. 1995. Drug release and surface morphology studies on salbutamol controlled release pellets. Drug Dev Ind Pharm 21:1303-1322.
14. Guo HX, Heinämäki JT, Yliruusi JK. 2002. Amylopectin as a non-traditional subcoating material for aqueous enteric film coating. Proc. 4th World Meeting ADRITELF/APGI/APV, Florence: 209.
15. Guo X, Heinämäki JT, Yliruusi JK. 2002. Amylopectin as a subcoating material improves the acidic resistance of enteric-coated pellets containing a freely soluble drug. Int J Pharm 235:79-86.
16. Chen C-M, Chou J, Weng T. 1999. Omeprazole formulation. US 6,077,541.
17. Chen C-M, Chou J, Weng T. 1997. Omeprazole formulation. US-Patent 6,096,340.
18. Chen C-M, Chou J, Kositprapa U. 1998. Omeprazole formulation. US-Patent 6,174,548 B1.
19. Lundberg PJ, Lövgren K. 1996. New pharmaceutical formulation and process. WO-Patent 96/24338.
20. Nair R, Nyamweya N, Gönen S, Martinez-Miranda LJ, Hoag SW. 2001. Influence of various drugs on the glass transition temperature of poly(vinylpyrrolidone): A thermodynamic and spectroscopic investigation. Int J Pharm 225:83-96.
21. Riedel A, Leopold CS. 2005. Degradation of omeprazole induced by enteric polymer solutions and aqueous dispersions: HPLC investigations. Drug Dev Ind Pharm 31:151-160.
22. Arias MJ, Munoz P, Moyano JR, Gines JM, Novak C. 1998. Thermal study of different omeprazolegamma-CD co-ground systems. J Thermal Anal 51:937-980.
23. Arias MJ, Moyano JR, Munoz P, Gines JM, Justo A, Giordano F. 2000. Study of omeprazole-gamma-cyclodextrin complexation in the solid state. Drug Dev Ind Pharm 26:253-259.
24. Ruiz MA, Reyes I, Parera A, Gallardo V. 1998. Determination of the stability of omeprazole by means of differential scanning calorimetry. J Thermal Anal 51:29-35.
25. Verdonck E, Schaap K, Thomas LC. 1999. A discussion of the principles and applications of modulated temperature DSC (MTDSC). Int J Pharm 192:3-20.
26. +)-ATPase inhibiting 2-[(2-Pyridylmethyl)sulfinyl]benzimidazoles. 2. The reaction cascade induced by treatment with acids. Formation of 5H-Pyrido[1′,2′:4,5][1,2,4] thiadiazono[2,3-a]benzimidazol-13-ium salts and their reaction with thiols. J Org Chem 52:4582-4592.
27. Brändström A, Lindberg P, Bergman N-K, Grundevik I, Tekenbergs-Hjelte L, Ohlson K. 1989. Chemical reactions of omeprazole and omeprazole analogues. VI. The reactions of omeprazole in the absence of 2-mercaptoethanol. Acta Chem Scand 43:595-611.
28. Tabata T, Kashihara T, Hirai S, Kitamori N, Toguchi H. 1992. Stabilization of a new antiulcer drug (lansoprazole) in the solid dosage forms. Drug Dev Ind Pharm 18:1437-1447.
29. Tabata T, Makino T, Kikuta J-I, Hirai S, Kitamori N. 1994. Manufacturing method of stable enteric granules of a new antiulcer drug (lansoprazole). Drug Dev Ind Pharm 20:1661-1672.
30. Riedel A, Leopold CS. 2005. Quantification of omeprazole degradation by enteric coating polymers: An UV-VIS spectroscopy study. Pharmazie 60:126-130.
31. Brändström A, Lindberg P, Bergman N-K, Alminger T, Junggren UC. 1989. Chemical reactions of omeprazole and omeprazole analogues. I. A survey of the chemical transformation of omeprazole and its analogues. Acta Chem Scand 43:536-548.
32. Münzel K, Büchi J, Schultz D-E. 1959. Übung: Demineralisiertes und destilliertes Wasser. In: Galenisches Praktikum. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH.
33. Harwood RJ. 2000. Hydroxypropyl methylcellulose. In: Kibbe AH, Kibbe AHs, editors. Handbook of pharmaceutical excipients. Washington DC: American Pharmaceutical Association.
34. Pearnchob N, Siepmann J, Bodmeier R. 2003. Pharmaceutical applications of shellac: Moisture-protective and taste-masking coatings and extended-release matrix tablets. Drug Dev Ind Pharm 29:925-938.
35. Lehmann K. 1997. Chemistry and application properties of polymethacrylate coating systems. In: McGinity JW, editor. Aqueous polymeric coatings for pharmaceutical dosage forms. New York: Marcel Dekker.
36. Schmidt-Mende T. 2001. Freisetzung aus magensaftresistent überzogenen Arzneiformen [Thesis]. Düsseldorf: Heinrich-Heine- Universität.
37. Product information HPMCAS. 1998. ShinEtsu.
38. Product information HPMCP. 1998. ShinEtsu.
39. Pearnchob N, Bodmeier R. 2003. Dry polymer powder coating and comparison with conventional liquid-based coatings for Eudragit RS, ethylcellulose and shellac. Eur J Pharm Biopharm 56:363-369.
40. Gupta VK, Beckert TE, Deusch NJ, Hariharan M, Price JC. 2002. Investigation of potential ionic interactions between anionic and cationic polymethacrylates of multiple coatings of novel colonic delivery system. Drug Dev Ind Pharm 28:207-215.